IMCD Stock IMCD.AS
IMCD is a global distributor of specialty chemicals and food and nutrition ingredients, operating as an intermediary between chemical and ingredient producers and customers across sectors including food, pharmaceuticals, personal care, coatings, and industrials. IMCD stock (IMCD.AS): Half-year and annual results since 2022 from Half-Year Report and IR documents: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 07/2025, half-year reporting. Stock analysis by NadirAlpha. IMCD stock (IMCD.AS): listed on Euronext Amsterdam, WKN A116P8. NadirAlpha has evaluated 3 original documents, cross-checked every figure automatically and linked each to its source; sources as of 07/2025. Revenue H1 2025: EUR 770 million (+6% year on year). Latest reported (H1 2025): Cash earnings per share, Cash conversion margin, Conversion margin. Latest reading: Margin expanding, Acquisition, Revenue accelerating.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
IMCD Current Status
Where IMCD stands after the report for H1 2025: what changed in revenue, earnings and outlook, written editorially from the original report. NadirAlpha methodology
Assessment by NadirAlpha, as of H1 2025.
“In the first half of 2025 we delivered forex adjusted gross profit growth of 7% and EBITA growth of 4%. We completed six acquisitions across our three regions to further strengthen our capabilities in a range of core market segments. Under challenging and unpredictable macro-economic market conditions, I am assured by the resilience of our asset-light business model and thankful to our teams for their continued growth focus. While these challenging conditions may persist, we are well positioned for the future through our leading speciality focused portfolio, geographic and market diversity combined with advanced digital and supply chain capabilities.”
IMCD Stock: Key Figures (€ million)
Revenue, margin, earnings and EPS of IMCD per fiscal year, half-year and quarter in € million, as of H1 2025, as reported in the filing; restatements show the most recent filing version. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Net income | EPS (€) | OCF | Source |
|---|---|---|---|---|---|---|
| FY2024 | 4,727.6 | 425.1 | 278.2 | 4.86 | 279.2 | 2 |
| FY2023 | 4,442.6 | 428.5~ | 292.3 | 5.13 | 420 | 2 |
Half-years
| Period | Published | Revenue | Op. income | Net income | EPS (€) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2025-H1* | 2025-07-30 | 769.9~ | 218.3 | 129.7 | 2.20 | 102.4 | 190.4 | 1,186.5 | 103 |
| 2024-H2* | 2025-03-05 | 3,999 | 205 | 137 | – | – | 525.4 | 1,171.9 | 102 |
| 2024-H1* | 2024-07-31 | 728.6~ | 220.1 | 141.3 | 2.52 | 140.5 | 223.8 | 1,016.2 | 1 |
| 2023-H2* | 2025-03-05 | 3,704.2 | 189.5 | 139.6 | 2.45*≈ | 231.4 | 394.5 | 856 | 102 |
| 2023-H1* | 2024-07-31 | 738.4~ | 239 | 152.7 | 2.72 | 167.3 | – | – | 101 |
IMCD Balance Sheet & Cash Flow (€ million)
Point-in-time balance sheet items of IMCD (cash, financial debt) and cash flow items per fiscal year, half-year and quarter, derived values with their formula in the popover. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Published | Cash | Debt | Net Debt | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|
| FY2024 | 2025-03-05 | 525.4 | 1,697.3 | 1,171.9 | 279.2 | 14.1 | 265.1 | 2 |
| FY2023 | 2025-03-05 | 394.5 | 1,250.5 | 856 | 420 | 21.2~ | 398.8~ | 2 |
| FY2022 | 2023-02-28 | 222 | 952.9 | 730.9 | 298.8 | 10.9 | 288 | – |
Half-years
| Period | Published | Cash | Debt | Net Debt | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|
| 2025-H1 | 2025-07-30 | 190.4 | 1,377 | 1,186.5 | 107.3 | 4.9 | 102.4 | 103 |
| 2024-H2 | 2025-03-05 | 525.4 | 1,697.3 | 1,171.9 | 132.5 | 7.8 | – | 102 |
| 2024-H1 | 2024-07-31 | 223.8 | 1,240 | 1,016.2 | 146.7 | 6.2 | 140.5 | 1 |
| 2023-H2 | 2025-03-05 | 394.5 | 1,250.5 | 856 | 248.1 | 16.7 | 231.4 | 102 |
| 2023-H1 | 2024-07-31 | – | – | – | 171.9 | 4.6 | 167.3 | 101 |
| 2022-H2 | 2023-02-28 | 222 | 952.9 | 730.9 | – | – | – | – |
IMCD Stock: Price & Chart
Chart and key figure trend of IMCD stock: the TradingView chart starts only on click, the key figure chart comes from the core tables up to H1 2025. NadirAlpha methodology
No embedded chart is licensed for this exchange; the chart opens on TradingView in a new tab.
IMCD Event Timeline
This timeline collects the material events of IMCD from the original reports: guidance changes, revenue and margin signals, strategy shifts, product and M&A announcements, grouped by quarter. NadirAlpha methodology
2025 · 7 events
Revenue increased 4% to EUR 2,474 million, driven by 2% organic growth and 4% contribution from acquisitions 3
Six acquisitions completed year to date: Ferrer Alimentación, TECOM, Apus Química, YCAM, Daoqin, and Trichem 3
“It would not have been possible without our nearly 5000 colleagues, and there is so much excellence and commitment, thank you!”
Net result decreased 5% to 278.2 million; diluted EPS declined to 4.86 from EUR 5.13 in 2023 2
Three consecutive quarters of organic revenue and operating EBITA growth achieved following a soft Q1 2024 2
Operating EBITA margin declined 0.4 percentage points to 11.2% from 11.6% in 2023, driven by inflation-related own cost growth outpacing gross profit gains 2
12 acquisitions completed in 2024 including Valuetree, Euro Chemo-Pharma, Gova, Selechimica and Blumos Group across all regions; two further agreements signed for 2025 closing 2
2024 · 2 events
“In the second quarter of the year, we delivered moderate organic EBITA growth based on a forex adjusted gross profit growth of 11%. This second quarter gross profit growth was a combination of organic growth and a positive contribution from recent acquisitions. We remain confident that our strong commercial teams, digital and logistic infrastructure and the resilience of our business model, will continue to contribute value to our stakeholders and sustain our growth trajectory.”
Operating EBITA declined 4% to EUR 270 million in H1 2024; Americas organic EBITA declined 19% organically 1
11 acquisitions completed year-to-date across India, Colombia, China, Malaysia, Australia/New Zealand, Latin America, Benelux, Italy, UK and Spain 1
IMCD Business Model
The IMCD business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology
IMCD is a global distributor of specialty chemicals and food and nutrition ingredients, operating as an intermediary between chemical and ingredient producers and customers across sectors including food, pharmaceuticals, personal care, coatings, and industrials. IMCD earns revenue through the sale of distributed products, with gross profit serving as the primary performance measure given the pass-through nature of input costs in its distribution model. The business is asset-light and expertise-driven, with value derived from technical knowledge, long-term supplier relationships, and a geographically diversified commercial network. Geographic expansion through bolt-on acquisitions is a regular component of the company's portfolio growth.
IMCD Stock: Share-Price Drivers
What determines the business trajectory of IMCD according to management, summarised from the reports up to H1 2025. NadirAlpha methodology
IMCD has completed a dense series of acquisitions through 2024 and into 2025, including TECOM Ingredients, Apus Quimica and Trichem Healthcare closing in H1 2025, extending its regional and end-market reach 3; the programme is funded in part through a EUR 500 million corporate bond and a EUR 300 million share offering placed in 2024 2.
IMCD's EMEA segment is the largest revenue contributor at 1,065.1 million in 2025-H1 with growth stated at 4.0% and a margin of 11.7% 3.
Americas revenue of 769.9 million in 2025-H1 grew at a rate stated as 6.0%, the fastest of the three regions, at a 10.8% margin 3.
Asia-Pacific revenue of 638.6 million in 2025-H1 rose at a rate stated as 1.0%, broadly flat, though it carried the highest segment margin at 13.5% 3.
IMCD closed multiple deals in H1 2025 (TECOM Ingredients, Apus Quimica, Trichem Healthcare on 3 July and 26 June 2025, plus the remaining 30% of Megasetia in January 2025), continuing the 2024 cadence of Blumos, Cobapharma, CJ Shah and others, indicating the acquisition engine is still active 3 2.
IMCD raised a EUR 500 million corporate bond in September 2024 and placed a EUR 300 million share offering in November 2024, supporting the funding of further acquisitions 2.
Growth across the group is characterised as decelerating while profitability is holding, with no fresh guidance stated 3.
Sector trend: Across IMCD's chemical and ingredient distribution regions, demand is growing but at a slowing pace, with the Americas leading at a stated 6.0% and Asia-Pacific broadly flat at a stated 1.0% 3. Segment margins remain differentiated, highest in Asia-Pacific at 13.5% and lowest in the Americas at 10.8%, pointing to stable rather than expanding profitability 3.
IMCD Revenue by Type (as of 2025-H1 · EUR million · 3/3)
The segments of IMCD in the company's own definition, each row with its basis (3, 6 or 12 months), rows in grey are no longer reported separately. NadirAlpha methodology
| Segment | Since | Revenue | Growth | Margin | Source |
|---|---|---|---|---|---|
| Period 2025-H1 (6M) | |||||
| EMEA | 2024-H1 | 1,065.1 | 4% | 11.7% | 3 |
| Americas | 2024-H1 | 769.9 | 6% | 10.8% | 3 |
| Asia-Pacific | 2024-H1 | 638.6 | 1% | 13.5% | 3 |
IMCD Products & announcements (8/8 active+recent)
8 product announcements of IMCD since 2022, grouped by year; active means still mentioned in the most recent reports, nothing is deleted. NadirAlpha methodology
Status: Launched
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2024 | |||
| IMCD Rising Leaders programme launch | 2024-11 | 2 | |
| Smart Farm Project launched at Jalan Empat Primary School in Malaysia | 2024 | 2 | |
| Sea Safe and Sun programme launched in France | 2024 | 2 | |
| Science Room added to Firefly Science Truck project in Türkiye | 2024 | 2 | |
| Pharmaceuticals Technical Centre expansion in Jakarta | 2024 | 2 | |
| New Milan office and laboratory facilities opened | 2024 | 2 | |
| Microbiology laboratory launched in Jakarta | 2024 | 2 | |
| 30th Food & Nutrition laboratory opened in Vienna | 2024 | 2 | |
IMCD Transactions & Events (41)
41 transactions and events of IMCD from the original reports, financing measures and management changes are not listed here, cancelled items in grey. NadirAlpha methodology
Acquisitions by IMCD
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2025 | |||
| TECOM Ingredients acquisition | 2025-07 | Completed | 3 |
| Apus Química acquisition | 2025-07 | Completed | 3 |
| Trichem Healthcare acquisition | 2025-06 | Completed | 3 |
| Ferrer Alimentación acquisition | 2025-06 | Completed | 3 |
| Acquisition agreements signed for Q2 2025 closing | 2025-06 | Announced | 2 |
| Daoqin Biological Technology acquisition (2×) | 2025-05 | Completed | 2 |
| YCAM Corporation | 2025-04 | Completed | 3 |
| Sanrise remaining 30% interest acquisition (5×) | 2025-04 | Completed | 3 |
| 2024 | |||
| Importadora y Distribuidora Blumos SpA and related entities | 2024-11 | Completed | 2 |
| EUR 300 million share offering | 2024-11 | Completed | 2 |
| 2,120,141 ordinary shares issuance via accelerated bookbuild | 2024-11 | Completed | 2 |
| EUR 500 million bond issuance (2x) | 2024-09 | Completed | 2 |
| Arena Pharmaceuticals Ltd. | 2024-07 | Completed | 1 |
| Guangzhou RBD Chemical Co Ltd | 2024-06 | Completed | 1 |
| Gova B.V. | 2024-06 | Completed | 1 |
| ResChem Technologies Pty Ltd and ResChem Trust (2x) | 2024-05 | Completed | 2 |
| Bretano (Costa Rica El Salvador Guatemala Mexico) | 2024-05 | Completed | 1 |
| CJ Shah business lines acquisition | 2024-02 | Completed | 2 |
| Valuetree Ingredients acquisition | 2024-01 | Completed | 2 |
| Valuetree acquisition | 2024 | Completed | 2 |
| Valuetree Ingredients Private Limited | 2024 | Completed | 2 |
| Tradeimpex acquisition | 2024 | Completed | 2 |
| Signet Excipients remaining 30% acquisition | 2024 | Completed | 2 |
| Selechimica S.R.L. (2x) | 2024 | Completed | 1 |
| Sanrise acquisition | 2024 | Completed | 2 |
| ResChem acquisition | 2024 | Completed | 2 |
| RBD acquisition | 2024 | Completed | 2 |
| Needfill acquisition | 2024 | Completed | 2 |
| Joli Foods S.A.S. (2x) | 2024 | Completed | 2 |
| Gova acquisition | 2024 | Completed | 2 |
| Gova Ingredients acquisition | 2024 | Completed | 2 |
| EuroChem Pharma acquisition | 2024 | Completed | 2 |
| Euro-Chemo-Pharma acquisition (4×) | 2024 | Completed | 2 |
| Daoqin acquisition agreement (3×) | 2024 | Announced | 2 |
| Cobapharma S.L.U. (2×) | 2024 | Completed | 2 |
| CJ Shah & Company | 2024 | Completed | 2 |
| Brylchem Group acquisition | 2024 | Completed | 2 |
| Bretano Group | 2024 | Completed | 2 |
| Blumos acquisition | 2024 | Completed | 2 |
| Arena acquisition | 2024 | Completed | 2 |
| Acquisitions completed in 2024 | 2024 | Completed | 2 |
IMCD Risks (65 since the annual report of 2025-03-05, 68 tracked in total)
Which risks IMCD has named since the annual report, company-specific first, generic standard risks in the expandable part; first mention refers to the document base from 2023. NadirAlpha methodology
Category: MarketCustomersMacroCyberESGFinancialSupply chainPeopleLegalRegulatoryCompetitionTechnology
| Risk | Category | Last reported |
|---|---|---|
| IMCD: first mention in IR-Report report of 2025-07-30 (2025-H1), source 3 | ||
| Industrial segment has cyclical nature dependent on housing, automotive, and oil & gas markets | = | |
| IMCD: first mention in IR-Report report of 2024-07-31 (2024-H1), source 1 | ||
| Long-term relationships with suppliers of specialty chemicals provide stability | 2025-H1 2025-07-30 3 | |
| Macro-economic and political uncertainty make future developments difficult to predict | 2025-H1 2025-07-30 3 | |
| IMCD: first mention in IR-Annual annual report of 2025-03-05 (FY2024), source 2 | ||
| Cyberattacks, malware, natural disasters and system failures could disrupt operations and breach sensitive data | = | |
| Poorly managed community initiatives could create dependency rather than empowerment | = | |
| Non-diverse decision-making groups risk poor decisions group-think and increased costs | = | |
| Increased working capital investments impacting cash conversion | = | |
| Flood damage to warehouses and inventory could result in significant capital and remediation costs | = | |
| Customer credit risk influenced by individual creditworthiness and industry concentration factors | = | |
| Leverage covenant of 3.75 times EBITDA applicable to revolving credit facility | = | |
| Environmental accidents could lead to increased regulatory scrutiny and financial liabilities. | = | |
| Limited direct influence over upstream suppliers' working conditions despite outsourced operations model. | = | |
| Declining customer demand driven by macroeconomic conditions and consumer preference shifts toward sustainable products | = | |
| Approximately 3,400 suppliers and portfolio of about 52,000 products | = | |
| Suppliers unable to provide low-carbon products at required pace limits product choice | = | |
| Supplier relationship termination or product shortages could materially affect product portfolio and profit margins | = | |
| Employee turnover 19% globally; 23.8% in Americas and Asia-Pacific regions | = | |
| Workplace accidents in labs and warehouses create personal injury and legal liability risks | = | |
| High employee turnover impacts innovation ability and increases recruitment costs | = | |
| Loss of key managerial, technical and sales personnel could materially harm company performance and customer relationships | = | |
| 23% of workforce covered by collective labour agreements; declining from 28% in 2023 | = | |
| Human rights or labour practice violations risk lawsuits fines and reputational damage | = | |
| Commercial management roles 32% women; target minimum 33% not achieved in 2024 with 36% appointments | = | |
| Unadjusted gender pay gap of 20.8% primarily due to occupational distribution with women in lower-paid roles | = | |
| Highly educated technical workers in high demand; Asia-Pacific and newly acquired businesses show higher attrition | = | |
| Competition for highly qualified chemical and ingredients expertise | = | |
| Confirmed compliance incidents concerning corruption, bribery or employee fraud pose ongoing risks | = | |
| Allegations of greenwashing from misaligned Sustainable Solutions portfolio could damage reputation | = | |
| Handling hazardous chemicals creates risk of personal injuries, environmental incidents, and reputational damage. | = | |
| Exposure to health, safety and environmental risks from handling chemicals; non-compliance could cause reputational and financial damage | = | |
| Non-compliance with REACH and TSCA regulations could restrict product distribution and result in penalties. | = | |
| Acquisition risks including integration failures, impairment losses on intangible assets, and cultural fit challenges | = | |
| Cybersecurity attacks could compromise operations and disrupt business functions | = | |
| Security incidents involving customer contact details and data breaches threaten data protection | = | |
| Diversity equity inclusion initiatives require dedicated resources and cultural transformation | = | |
| Inadequate diversity efforts could damage employer brand and investor confidence | = | |
| High capital expenditure costs for diversifying and decarbonising products and services | = | |
| Negative impact of foreign currency exchange rate developments on revenue and operating results | = | |
| Foreign currency exposure on sales, purchases and borrowings denominated in non-functional currencies | = | |
| Foreign currency exchange rate impacts on consolidated results | = | |
| Exposure to interest rate risk on variable rate loans; hedging via interest rate swaps applied as needed | = | |
| Risk of difficulty meeting financial obligations due within twelve months under stressed conditions | = | |
| Loss or misuse of customer data poses reputational and financial risks | = | |
| Extreme weather events causing value chain disruptions and longer lead times | = | |
| Dependence on third-party logistics providers for decarbonization goals | = | |
| Rising temperatures increase extreme rainfall and flooding risk to operations | = | |
| Operations in emerging markets expose IMCD to various operational and regulatory risks. | = | |
| Increased frequency and intensity of floods disrupts operations and supply chains | = | |
| Ongoing global geopolitical tensions affecting market demand and volatility | = | |
| Volatile, uncertain, complex and ambiguous (VUCA) market conditions influencing customer and investor behaviour | = | |
| Water scarcity and poor water management practices risk regulatory fines | = | |
| Decreased revenue as demand for emissions-intensive products declines in net-zero scenario | = | |
| Transport sector decarbonisation costs passed through to IMCD via third-party logistics providers | = | |
| Technology and process improvements may lead to workforce restructuring impacts | = | |
| Non-compliance with anti-corruption and anti-bribery laws could result in fines, prosecution and reputational harm | = | |
| Anti-competitive behaviour risks managed through competition law training and compliance procedures | = | |
| Increased climate-related reporting obligations on specific products | = | |
| Exposure to international legal and compliance risks across multiple jurisdictions including antitrust, sanctions and export controls | = | |
| Failure to meet energy efficiency and GHG emission targets risks fines and regulatory penalties | = | |
| Increasing ESG and sustainability regulatory requirements | = | |
| Trade sanctions and export control regulations require ongoing screening and compliance monitoring | = | |
| Complexity of tax legislation and interpretation differences with tax authorities create compliance risks | = | |
| Need for continued digital infrastructure investment and modernization | = | |
| Reliance on maintaining strong partnerships and distributorships with key suppliers and principals | = | |
| IMCD: first mention in IR-Report report of 2024-07-31 (2024-H1), source 1 | ||
| Operational risks arise from legal and regulatory requirements | FY2024 2025-03-05 2 | |
IMCD Reported KPIs (as disclosed) (128)
NadirAlpha collects 128 reported KPIs of IMCD from the filings up to H1 2025; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| IMCD, published 2025-07-30, period 2025-H1 | ||
| Operating EBITA as percentage of revenue | 11.1% | 3 |
| Net working capital days | 69 | 3 |
| Leverage ratio | 2.6 | 3 |
| Gross profit as percentage of revenue | 25.6% | 3 |
| Gross profit | 634,298 | 3 |
| Conversion margin | 43.4% | 3 |
| Cash earnings per share | 2.94 | 3 |
| Cash conversion margin | 61.4% | 3 |
| IMCD, published 2025-03-05, period FY2024 | ||
| Women sub top management pct | 45% | 2 |
| Women sub top management commercial P&L pct | 32% | 2 |
| Women in sub top management | 45% | 2 |
| Women in management subtop | 45% | 2 |
| Women in commercial P&L roles | 32% | 2 |
| Women in commercial management | 32% | 2 |
| Women appointed sub top management pct | 45% | 2 |
| Women appointed sub top management commercial P&L pct | 36% | 2 |
| Upstream suppliers EcoVadis screened | 91% | 2 |
| TRIR rate 200k hours | 0.3 | 2 |
| training hours total | 107,538 | 2 |
| total tax expenses | EUR 101.8 million | 2 |
| TFS suppliers valid Ecocardis | 1,055 | 2 |
| taxonomy eligible opex percentage | 22% | 2 |
| taxonomy eligible capex percentage | 18% | 2 |
| taxonomy aligned opex percentage | 0% | 2 |
| taxonomy aligned capex percentage | 0% | 2 |
| Sustainalytics risk score | Low-risk score: 12.6 | 2 |
| Sustainalytics ESG risk rating | 12.6 | 2 |
| supervisory board women | 40% | 2 |
| spills chemical mishandling | 3 | 2 |
| security incidents customer data | 1 | 2 |
| scope 3 GHG emission intensity | +12% | 2 |
| scope 1 2 GHG emission intensity | +17% | 2 |
| revenues | 4,728 | 2 |
| revenue covered internal audit risk assessment | 98% | 2 |
| reported leverage | 2.2 | 2 |
| reported environmental incidents | 1 | 2 |
| reported child forced labour incidents | 0 | 2 |
| Recordable work-related injuries and illnesses | 18 | 2 |
| Public legal cases: corruption | 0 | 2 |
| Pillar II tax expense | EUR 0.6 million | 2 |
| Pending legal proceedings: antitrust | 0 | 2 |
| Parental leave take-up rate | 51% | 2 |
| Parental leave taken | 192 | 2 |
| Parental leave eligible | 373 | 2 |
| Operating EBITDA EMEA | 229 million | 2 |
| Operating EBITDA Asia Pacific | 162 million | 2 |
| Operating EBITDA Americas | 150 million | 2 |
| Operating EBITDA | 540 million | 2 |
| New hires FTE | 1,346 | 2 |
| New hires 2024 total | 853 | 2 |
| Mass of product sold | 1,233,962 tonnes | 2 |
| Management board women | 33% | 2 |
| Local sourcing of services | 85% | 2 |
| Leverage loan documentation | 2.1 | 2 |
| Leverage including pro forma results | 2.2 | 2 |
| ISS ESG rating | C+ (Prime) | 2 |
| Substantiated hotline incidents | 2 | 2 |
| Global effective tax rate | 26.8% | 2 |
| GHG emissions scope 3 | 5,093,167 | 2 |
| GHG emissions scope 1+2 market-based | 11,807 | 2 |
| GHG emissions scope 1+2 location-based | 11,930 | 2 |
| FTE | 5,126 FTE | 2 |
| Executive committee women & non-Europeans % | 25% | 2 |
| Ethics & compliance hotline reports received | 10 | 2 |
| Ethics & compliance hotline reports investigated | 2 | 2 |
| Entities reviewed by internal audit | 127 | 2 |
| Emissions intensity scope 3 | 8,900 | 2 |
| Emissions intensity scope 1+2 market-based | 21 | 2 |
| Emissions intensity scope 1+2 location-based | 21 | 2 |
| EcoVadis rating | Gold | 2 |
| EcoVadis gold score | 74 | 2 |
| EBITA CAGR 5-year | 17% | 2 |
| Downstream suppliers ESG compliance | 96% | 2 |
| Downstream suppliers EcoVadis screened | 89% | 2 |
| Dividend per share | 2.15 | 2 |
| Dividend paid | EUR 128m | 2 |
| Distributed merchandise | 1.2 mln tonnes | 2 |
| direct energy carriers biogenic | 301 | 2 |
| digital compliance training completion | 90% | 2 |
| data breaches reported to authorities | 0 | 2 |
| cybersecurity training completion | 98% | 2 |
| compliance incidents corruption bribery fraud | 1 | 2 |
| CEO to median compensation ratio | 27.4 | 2 |
| CDP rating | B | 2 |
| CDP climate change rating | B | 2 |
| cash corporate income tax payments | EUR 139.6 million | 2 |
| business partner contracts terminated for compliance | 0 | 2 |
| average training hours | 21 | 2 |
| antitrust violations reported | 0 | 2 |
| anti-corruption training completion | 94% | 2 |
| anti-corruption policies communicated to business partners | 100% | 2 |
| adjusted leverage ratio | 2.2 | 2 |
| Working capital | 907.5 | 2 |
| Weighted average number of shares | 57,214,054 | 2 |
| Total working capital days | 69 | 2 |
| Rate of recordable work-related injuries | 0.36 | 2 |
| Rate of high consequence work-related injuries | 0.00 | 2 |
| Operating EBITA % of revenue | 11.2% | 2 |
| Number of customers growth | 8% | 2 |
| Net working capital | 907.5 (EUR EUR MILLION) | 2 |
| Net revenue total | 4,728 (EUR EUR m) | 2 |
| Lost time injuries related to ill health | 365 | 2 |
| Lost time injuries (LTI) | 601 | 2 |
| Liabilities to personnel | 675 | 2 |
| Gross profit margin | 27.8% | 2 |
| Free cash flow | 449.7 | 2 |
| Equity | 2,215.1 (EUR EUR MILLION) | 2 |
| Earnings per share | 4.86 | 2 |
| Dividend per share | 2.15 | 2 |
| Depreciation of property, plant and equipment | 41,411 | 2 |
| Conversion margin | 44.2% | 2 |
| Cash earnings per share | 6.34 | 2 |
| Cash earnings per share | 6.34 | 2 |
| Cash conversion margin | 82.7% | 2 |
| Cash conversion margin | 82.7% | 2 |
| Cash EPS growth (weighted) | (1%) | 2 |
| Average wages and salaries growth | 1% | 2 |
| Adjusted leverage ratio | 2.2 | 2 |
| Adjusted leverage ratio | 2.2 | 2 |
| Adjusted equity | 2,215,149 | 2 |
| Adjusted Operating EBITDA | 543.6 (EUR EUR MILLION) | 2 |
| Accrued interest expenses | 23,001 (EUR EUR 1,000) | 2 |
| IMCD, published 2024-07-31, period 2024-H1 | ||
| Operating EBITA as a % of revenue | 11.3% | 1 |
| Operating EBITA | 269,808 | 1 |
| Leverage ratio | 2.9 times EBITDA | 1 |
| Conversion margin | 44.5% | 1 |
| Cash earnings per share | 3.23 | 1 |
| Cash conversion margin | 79.8% | 1 |
IMCD Development
How IMCD has developed since 2022: one paragraph per period on revenue, earnings, cash flow and drivers, most recent period first, grouped by year. NadirAlpha methodology
FY2025: IMCD
In the first half of 2025, IMCD reported revenue of EUR 2,474 million, an increase of 4% driven by 2% organic growth and a 4% contribution from acquisitions 3. Gross profit rose 5% to EUR 634 million, with the gross profit margin at 25.6% compared with 25.4% in the prior-year period 3. Operating EBITA increased 2% to EUR 275 million on a reported basis 3. Six acquisitions were completed year to date, including Ferrer Alimentación, TECOM, Apus Química, YCAM, Daoqin, and Trichem 3. Free cash flow was EUR 173 million, lower than EUR 221 million in the prior-year period, with net debt rising to EUR 1,542.6 million from EUR 1,281.6 million following acquisition spend and a dividend payment 3.
FY2024: IMCD
IMCD reported full-year 2024 revenue of 4,727.6 million, up 6% (8% on a constant currency basis), as acquisition growth of 8% more than offset an organic revenue decline of 1% and a 1% currency headwind 2. Operating EBITA grew 3% to EUR 530.9 million, while the operating EBITA margin contracted 0.4 percentage points to 11.2% as inflation-driven own cost growth outpaced gross profit gains 2. IMCD completed 12 acquisitions during the year across all three regions, contributing EUR 209.5 million to revenue, and achieved three consecutive quarters of organic revenue growth after a soft first quarter 2. Net result decreased 5% to 278.2 million, with diluted EPS declining to 4.86 from EUR 5.13 in 2023; in the second half, IMCD issued a EUR 500 million fixed-rate bond in September and raised EUR 300 million through an accelerated bookbuild share offering in November 2024 2.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
All original documents NadirAlpha used for this report on IMCD stock: quarterly and annual reports, earnings releases and investor relations documents, sorted by publication, the document type is the link. NadirAlpha methodology
| # | Document type | Published |
|---|---|---|
| #1 / #101 | IR-Report report | 2024-07-31 |
| #2 / #102 | IR-Annual annual report | 2025-03-05 |
| #3 / #103 | IR-Report report | 2025-07-30 |
IMCD Stock FAQ
Which additional key figures does IMCD report?
As reported for H1 2025: Cash earnings per share, Cash conversion margin, Conversion margin, Leverage ratio, Operating EBITA as percentage of revenue, Gross profit as percentage of revenue. The chapter Reported KPIs lists every value with its source. Revenue is broken down by EMEA, Americas, Asia-Pacific.
Does IMCD pay a dividend?
The filings report on the dividend; most recent entry: dividend per share 2.15 (FY2024) (as reported, no assessment of our own). Details with source links are in the report chapters.
Where can I find the official investor relations documents of IMCD?
NadirAlpha links all 3 original filings used (IR documents) in the sources chapter: report, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.